Literature DB >> 11257775

Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?

K Takahashi1, J Yoshida, M Nishimura, K Nagai.   

Abstract

OBJECTIVE: There is no standard treatment for diffuse malignant pleural mesothelioma. Sporadic extrapleural pneumonectomy for the disease in off-protocol set has been performed when the disease was judged as being confined to a hemithorax. SUBJECT: To evaluate the role of extrapleural pneumonectomy in the treatment for the disease, cases that underwent surgery in a single institution are reported with descriptions of the stages based on the system from the International Mesothelioma Interest Group.
METHODS: Patients with diffuse malignant pleural mesothelioma treated with extrapleural pneumonectomy from 1989 to 1995 at the National Cancer Center Hospital East were reviewed.
RESULTS: Five patients underwent extrapleural pneumonectomy. All were male. Their ages ranged from 48 to 68 years. The disease was right-sided in two and left-sided in three. The histologic subtype was epithelial in three, and mixed epithelial and sarcomatous in the other two. Post-surgical pathologic stage was Ib (T1bN0M0) in three, III (T3N1M0) in one, and IV (T4N2M0) in one. There was no treatment-related death. Two cases with epithelial histology were alive with local recurrence on the chest wall at 75 months and at 51 months after surgery, respectively. A case with mixed epithelial and sarcomatous histology died of an esophageal cancer at 25 months after surgery. The two other cases died of the progressed disease at ten months and at four months after surgery, respectively.
CONCLUSION: Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma was concluded to be a treatment option in stage Ib cases with epithelial histology. To evaluate precisely the efficacy of surgery for the disease, a randomized control trial must be organized multi-institutionally.

Entities:  

Mesh:

Year:  2001        PMID: 11257775     DOI: 10.1007/bf02912122

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  19 in total

1.  A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.

Authors:  V W Rusch
Journal:  Lung Cancer       Date:  1996-02       Impact factor: 5.705

2.  Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients.

Authors:  P Ruffie; R Feld; S Minkin; Y Cormier; A Boutan-Laroze; R Ginsberg; J Ayoub; F A Shepherd; W K Evans; A Figueredo
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

3.  The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.

Authors:  V W Rusch; S Piantadosi; E C Holmes
Journal:  J Thorac Cardiovasc Surg       Date:  1991-07       Impact factor: 5.209

4.  Patterns of failure after trimodality therapy for malignant pleural mesothelioma.

Authors:  E H Baldini; A Recht; G M Strauss; M M DeCamp; S J Swanson; M J Liptay; S J Mentzer; D J Sugarbaker
Journal:  Ann Thorac Surg       Date:  1997-02       Impact factor: 4.330

5.  Calretinin: a novel immunocytochemical marker for mesothelioma.

Authors:  C Doglioni; A P Dei Tos; L Laurino; P Iuzzolino; C Chiarelli; M R Celio; G Viale
Journal:  Am J Surg Pathol       Date:  1996-09       Impact factor: 6.394

6.  Malignant pleural mesothelioma: a survival study.

Authors:  J C Harvey; E H Fleischman; A R Kagan; O E Streeter
Journal:  J Surg Oncol       Date:  1990-09       Impact factor: 3.454

7.  Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up.

Authors:  T L Moskal; T J Dougherty; J D Urschel; J G Antkowiak; A M Regal; D L Driscoll; H Takita
Journal:  Ann Thorac Surg       Date:  1998-10       Impact factor: 4.330

8.  Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.

Authors:  N G Ordóñez
Journal:  Am J Surg Pathol       Date:  1998-10       Impact factor: 6.394

9.  The importance of surgical staging in the treatment of malignant pleural mesothelioma.

Authors:  V W Rusch; E Venkatraman
Journal:  J Thorac Cardiovasc Surg       Date:  1996-04       Impact factor: 5.209

10.  Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.

Authors:  D J Sugarbaker; G M Strauss; T J Lynch; W Richards; S J Mentzer; T H Lee; J M Corson; K H Antman
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.